Antibodies News and Research

RSS

Synthetic drugs treat Crohn's disease in mice

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.

26 Dec 2011

Researchers discover that neutrophils exist in the spleen

For the first time, it has been discovered that neutrophils exist in the spleen without there being an infection.

26 Dec 2011

LRI praises U.S. Congress for legislation that addresses early lupus detection and treatment

A top legislative priority of the Lupus Research Institute (LRI) -- funding for a nationwide lupus education effort for healthcare providers -- is included in the Fiscal 2012 omnibus appropriations bill (H.R. 2055) signed into law today by President Obama after passing in the House of Representatives and the Senate.

26 Dec 2011

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

Potential new strategy against bacteria with multi-drug resistant organisms

Vaccines with broader reach might be made by stimulating specialized immune cells to recognize foreign cell membrane proteins that are shared across bacterial species, say researchers from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine in a report published online today in Immunity.

23 Dec 2011

FLT-PET imaging can effectively detect mantle cell lymphoma

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer.

22 Dec 2011

Researchers evaluate Clade C HIV envelope protein in Phase I trial

In the first clinical trial of an injectable vaccine containing trimeric HIV envelope protein (gp140) relevant to the predominant strain of HIV in Africa, researchers from four UK academic centers (St George's University London, Imperial College, Hull York Medical School (HYMS; University of York) and the Medical Research Council Clinical Trial Unit) and from the Infectious Disease Research Institute (IDRI) have come together to evaluate whether the vaccine is safe for use in human volunteers.

22 Dec 2011

University of Oxford scientists develop new candidate malaria vaccine

A new candidate malaria vaccine with the potential to neutralise all strains of the most deadly species of malaria parasite has been developed by a team led by scientists at the University of Oxford.

21 Dec 2011

arGEN-X to advance SIMPLE Antibody platform for treatment of autoimmune disorders

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets.

19 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

FIND, NUS collaborate to identify novel biomarkers for TB diagnosis

A research team from the National University of Singapore (NUS) Singapore Lipidomics Incubator (SLING) is collaborating with the Foundation for Innovative New Diagnostics (FIND) to identify novel target molecules to be employed as biomarkers for the detection of active tuberculosis.

15 Dec 2011

Fresh cells can pep talk immune cells exhausted by HIV or hepatitis C

Chronic infections by viruses such as HIV or hepatitis C eventually take hold because they wear the immune system out, a phenomenon immunologists describe as exhaustion.

14 Dec 2011

Research on pancreatic cancer diagnostic test wins QED award

Hwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University and co-director of the Jefferson Pancreatic, Biliary and Related Cancers Center, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center's QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.

14 Dec 2011

Scientists discover how intestinal tract influences B cells to prevent infection

Researchers at the University of Toronto have found an explanation for how the intestinal tract influences a key component of the immune system to prevent infection, offering a potential clue to the cause of autoimmune disorders like rheumatoid arthritis and multiple sclerosis.

13 Dec 2011

Study describes new method that synthesizes novel anti-HIV protein

The most abundant and important molecules in all living organisms are proteins; after all they manage to participate in every single one of life's essential reactions. So it is easy to see why scientists have been making such a fuss trying to learn how to synthesise them in laboratory as this would provide them with a tool of extraordinary potential. Unfortunately, this has not proved easy.

13 Dec 2011

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

13 Dec 2011

New findings from Micromet's blinatumomab phase 1 trial on DLBCL

New findings from a phase 1 trial presented yesterday at the 53rd Annual American Society of Hematology (ASH) Annual Meeting demonstrate Micromet's blinatumomab induces durable responses in patients with extensively pre-treated diffuse large B cell lymphoma.

12 Dec 2011

New research on diagnosis and treatment of leukemia to be presented at 53rd ASH meeting

Despite major research advances over the last several decades that have helped deliver improved therapeutic options for leukemia, the condition remains deadly. Specialists are in need of new options to help diagnose the condition earlier and new therapies that will extend patients' lives. New research addressing important updates on the diagnosis and treatment of leukemia will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Biochip can quickly predict blood poisoning

Is the patient suffering from blood poisoning? To answer this question, the doctor draws a blood sample and sends it to a central laboratory for testing. This takes up valuable time, which could cost the patient his life. In future, physicians will be able to analyze blood there and then and have the results within twenty minutes.

12 Dec 2011

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011